|
1
|
Zhang S, Zheng R, Zeng H and Chen W: The
incidence differences among sex, geographical areas and mean age of
diagnosis for liver cancer in China, 1989-2008. Zhonghua Yu Fang Yi
Xue Za Zhi. 48:355–360. 2014.(In Chinese). PubMed/NCBI
|
|
2
|
Ma X, Liu XX and Wu XP: Incidence and
mortality of cancer in the registered regions of Sichuan in 2009. J
Prev Med Inf. 29:918–923. 2013.
|
|
3
|
Chen JG, Lu JH, Zhu YR, Zhu J and Zhang
YH: A thirty-one year prospective follow-up program on the HBsAg
carrier state and primary liver cancer in Qidong, China. Zhonghua
Liu Xing Bing Xue Za Zhi. 31:721–726. 2010.(In Chinese). PubMed/NCBI
|
|
4
|
Cheok CF, Verma CS, Baselga J and Lane DP:
Translating p53 into the clinic. Nat Rev Clin Oncol. 8:25–37. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu S, Zhao L, Yang J and Hu M: The
association between polymorphism of P53 Codon72 Arg/Pro and
hepatocellular carcinoma susceptibility: Evidence from a
meta-analysis of 15 studies with 3,704 cases. Tumour Biol.
35:3647–3656. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Forner A and Bruix J: Biomarkers for early
diagnosis of hepatocellular carcinoma. Lancet Oncol. 13:750–751.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Insinga A, Cicalese A, Faretta M, Gallo B,
Albano L, Ronzoni S, Furia L, Viale A and Pelicci PG: DNA damage in
stem cells activates p21, inhibits p53, and induces symmetric
self-renewing divisions. Proc Natl Acad Sci USA. 110:3931–3936.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Leu JI, Murphy ME and George DL: The p53
codon 72 polymorphism modifies the cellular response to
inflammatory challenge in the liver. J Liver. 2:1172013.PubMed/NCBI
|
|
9
|
Zhang YY, Yu HP and Fan XJ: Association of
p53 codon72 polymorphism and risk of hepatocellular carcinoma. J
Clin Oncol. 18:189–193. 2012.
|
|
10
|
Mou NN and Zhang L: Effects of p53 gene
codon 72 Arg/Pro polymorphisms on susceptibility of hepatocellular
carcinoma in patients with hepatitis B virus infection in Shandong
Province. J Hepatopancreatobilliary Surg. 25:381–384. 2013.
|
|
11
|
Zhu ZZ, Cong WM, Zhu GS, Liu SF, Xian ZH,
Wu WQ, Zhang XZ, Wang YH and Wu MC: Association of p53 codon 72
polymorphism with genetic susceptibility to hepatocellular
carcinoma in Chinese population. Zhonghua Yi Xue Yi Chuan Xue Za
Zhi. 22:632–635. 2005.(In Chinese). PubMed/NCBI
|
|
12
|
Ezzikouri S, El Feydi AE, Chafik A,
Benazzouz M, El Kihal L, Afifi R, Hassar M, Pineau P and Benjelloun
S: The Pro variant of the p53 codon 72 polymorphism is associated
with hepatocellular carcinoma in Moroccan population. Hepatol Res.
37:748–754. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sümbül AT, Akkız H, Bayram S, Bekar A,
Akgöllü E and Sandıkçı M: p53 codon 72 polymorphism is associated
with susceptibility to hepatocellular carcinoma in the Turkish
population: A case-control study. Mol Biol Rep. 39:1639–1647. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoon YJ, Chang HY, Ahn SH, Kim JK, Park
YK, Kang DR, Park JY, Myoung SM, Kim DY, Chon CY, et al: MDM2 and
p53 polymorphisms are associated with the development of
hepatocellular carcinoma in patients with chronic hepatitis B virus
infection. Carcinogenesis. 29:1192–1196. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Di Vuolo V, Buonaguro L, Izzo F, Losito S,
Botti G, Buonaguro FM and Tornesello ML: TP53 and MDM2 gene
polymorphisms and risk of hepatocellular carcinoma among Italian
patients. Infect Agent Cancer. 6:132011. View Article : Google Scholar
|
|
16
|
Lu SQ, Jia ST and Luo Y: Recent advances
in mutant p53 and novel personalized strategies for cancer therapy.
Yi Chuan. 33:539–548. 2011.(In Chinese). View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lv L, Wang P, Zhou X and Sun B:
Association between the p53 codon 72 Arg/Pro polymorphism and
hepatocellular carcinoma risk. Tumour Biol. 34:1451–1459. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang XF, Wei T, Liu XM, Liu C and Lv Y:
Impact of cigarette smoking on outcome of hepatocellular carcinoma
after surgery in patients with hepatitis B. PLoS One. 9:e850772014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Yang H and Cao J: Association
between alcohol consumption and cancers in the Chinese population -
a systematic review and meta-analysis. PLoS One. 6:e187762011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kapoor NR, Ahuja R, Shukla SK and Kumar V:
The HBx protein of hepatitis B virus confers resistance against
nucleolar stress and anti-cancer drug-induced p53 expression. FEBS
Lett. 587:1287–1292. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park SG, Min JY, Chung C, Hsieh A and Jung
G: Tumor suppressor protein p53 induces degradation of the
oncogenic protein HBx. Cancer Lett. 282:229–237. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hartwell HJ, Petrosky KY, Fox JG, Horseman
ND and Rogers AB: Prolactin prevents hepatocellular carcinoma by
restricting innate immune activation of c-Myc in mice. Proc Natl
Acad Sci USA. 111:11455–11460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Keng VW, Largaespada DA and Villanueva A:
Why men are at higher risk for hepatocellular carcinoma? J Hepatol.
57:453–454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Naugler WE, Sakurai T, Kim S, Maeda S, Kim
K, Elsharkawy AM and Karin M: Gender disparity in liver cancer due
to sex differences in MyD88-dependent IL-6 production. Science.
317:121–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
